Seok Joo Lee – CEO, ISU Abxis, South Korea
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
The Korea Medical Devices Industry Association (KMDIA) is a trade association committed to improving public health and development of the industry by advocating companies that manufacture, import, export, or sell medical devices since its foundation in 1999.
The Association has around 750 members, bringing these companies together to share information and experience to disseminate the latest technologies and facilitate access to high-quality, affordable medical devices in Korea. The KMDIA is a valuable partner to government authorities such as the Ministry of Health and Welfare and the Ministry of Food and Drug Safety actively presenting policy proposals and regulation ideas, while offering extensive support to Korean medical devices manufacturers compete and grow further in the global market.
The medical devices industry continues rapid growth despite economic slowdown across the world. The factors that drive such growth include: aging society, growing anti-aging industry as a result of higher income, greater interest in health and wellness, government policies that value higher standard of life, emerging latest technologies and biomedical innovation. The Korean government designated the medical devices industry as one of its priority “growth engines” aspiring to lift Korea to global top 5 in the industry by 2018.
The Association also supports foreign and multi-national medical devices companies by providing market intelligence and statistics while assisting them in regulatory and approval procedures. Local and foreign firms are brought together to enter into business discussion and invited to exhibitions hosted by the KMDIA. The MOUs with the counterparts in different regions, such as AdvaMed and EucoMed, are part of the efforts to build networks and promote interactions among member companies, to eventually promote Korea as an attractive market.
The KMDIA is a dedicated partner to all members who seek assistance and partnership.
Contact details:
8~9F, Yeosam Bldg, 123 Teheran-ro, Gangnam-gu, Seoul Korea (135-748)
Tel: +82 2 596 7404
Fax: +82 2 596 7401
kmdia@kmdia.or.kr
www.kmdia.or.kr
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview,…
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains…
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools,…
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated…
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
See our Cookie Privacy Policy Here
